First successful pregnancy outcome after twelve abortions in a Tunisian-woman with the rare p phenotype.


Journal

Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine
ISSN: 1953-8022
Titre abrégé: Transfus Clin Biol
Pays: France
ID NLM: 9423846

Informations de publication

Date de publication:
Aug 2021
Historique:
received: 08 02 2021
revised: 09 06 2021
accepted: 10 06 2021
pubmed: 22 6 2021
medline: 29 10 2021
entrez: 21 6 2021
Statut: ppublish

Résumé

Anti-PP1P k alloantibody, is produced in the serum of individuals with the rare p phenotype. It is associated with severe haemolytic transfusion reactions, recurrent spontaneous early abortions as well as haemolytic disease of the foetus and newborn. Anti-PP1P k alloimmunization in pregnancy differ from others in their physiopathology. It seems that the placenta would be the main target of anti-PP1P k antibody. This report concerns a 35 year old female, with a history of a high incidence (12) of early and recurrent miscarriages. She was found to have the extremely rare p phenotype and anti-PP1P k antibody in her serum. Her 13th pregnancy was successfully managed by plasmapheresis. No substitution fluid was added. Oral hydration was recommended before and after the apheresis sessions. 12 plasmapheresis cycles were performed before a healthy term female infant weighing 3kg600g, was delivered by caesarean section at 38 weeks of gestation. Plasmapheresis seems to be the treatment of choice in the management of anti-PP1P k fetomaternal incompatibilities. However in this case, we opted for an original and less expensive protocol. We did resort, neither to substitution fluid nor to intravenous immunoglobulin.

Identifiants

pubmed: 34153474
pii: S1246-7820(21)00085-9
doi: 10.1016/j.tracli.2021.06.003
pii:
doi:

Substances chimiques

Isoantibodies 0

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

283-286

Informations de copyright

Copyright © 2021 Société française de transfusion sanguine (SFTS). Published by Elsevier Masson SAS. All rights reserved.

Auteurs

H Zarrouk (H)

Immunohematology Laboratory National Center of Blood Transfusion, Tunis, Tunisia. Electronic address: zarrouk.hager@yahoo.fr.

H Kaabi (H)

Immunohematology Laboratory National Center of Blood Transfusion, Tunis, Tunisia.

M Chaabane (M)

Immunohematology Laboratory National Center of Blood Transfusion, Tunis, Tunisia.

L Halouani (L)

Private Hospital Les Jasmins, Tunis, Tunisia.

S Hmida (S)

Immunohematology Laboratory National Center of Blood Transfusion, Tunis, Tunisia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH